Abdurrahim Bakirhan
Research Subjects
Abdurrahim Bakirhan has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
Safak Yalcin Sahiner
Department of Psychiatry, Numune Research and Training Hospital, Ankara, Turkey
3 shared publicationsAli Çayköylü
Yıldırım Beyazıt University School of Medicine, Department of Psychiatry, Ankara
2 shared publications- Burcu Akın Sarı
Department of Child and Adolescent Psychiatry Başkent University Faculty of Medicine Ankara Turkey
2 shared publications Burcu Serim Demirgören
Department of Child and Adolescent Psychiatry, Dokuz Eylul University School of Medicine, Izmir, Turkey
2 shared publicationsBüşra Bahar Ataoğlu
2 shared publicationsErtuğrul Köroğlu
Boylam Psychiatry Hospital, Ankara, Turkey
2 shared publications
Latest Publications
- Open Access
- 29 December 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (12) , e0189373
Association of serum brain derived neurotropic factor with duration of drug-naive period and positive-negative symptom scores in drug naive schizophrenia
The aim of this study was to compare the serum brain derived neurotropic factor (BNDF) levels of patients with schizophrenia who had never received an antipsychotic treatment with those of a control group. Also, to analyze the relationship between the Positive and Negative Symptom Scale (PANSS) scores and BDNF levels of the patients during the period they were drug-naive. The sample of the study comprised patients who presentedto the Psychiatry Clinic and were admitted after a distinctive schizophrenia diagnosis was made in accordance with the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) diagnosis classification and who were not using and never had any antipsychotic medicine. A total of 160 participants were included in the study, 80 of whom had schizophrenia patients and 80 constituted the age- and sex-matched healthy control group. Before the start of the treatment, the serum samples to be checked for the BDNF levels were collected from the patients. The difference between the average BDNF levels of the groups were statistically significant (t = -5.25; p˂.001). An analysis as to whether there was a relation between the BDNF levels and the drug-naïve duration indicated no correlations. An examination of the relationship between PANSS scores and BDNF levels of the patients yielded no correlations. Serum BDNF levels seem to be one of the indicators of schizophrenia and its progress; nevertheless, we still do not have sufficient information about this neurotropic factor. In light of our study, the neurodevelopmental changes that occur at disease onset of the illness prominently affect the progress of the illness, which highlights the importance of the treatment in the early stages.
- 29 December 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (12) , e0189373
Open AccessAssociation of serum brain derived neurotropic factor with duration of drug-naive period and positive-negative symptom scores in drug naive schizophrenia
The aim of this study was to compare the serum brain derived neurotropic factor (BNDF) levels of patients with schizophrenia who had never received an antipsychotic treatment with those of a control group. Also, to analyze the relationship between the Positive and Negative Symptom Scale (PANSS) scores and BDNF levels of the patients during the period they were drug-naive. The sample of the study comprised patients who presentedto the Psychiatry Clinic and were admitted after a distinctive schizophrenia diagnosis was made in accordance with the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) diagnosis classification and who were not using and never had any antipsychotic medicine. A total of 160 participants were included in the study, 80 of whom had schizophrenia patients and 80 constituted the age- and sex-matched healthy control group. Before the start of the treatment, the serum samples to be checked for the BDNF levels were collected from the patients. The difference between the average BDNF levels of the groups were statistically significant (t = -5.25; p˂.001). An analysis as to whether there was a relation between the BDNF levels and the drug-naïve duration indicated no correlations. An examination of the relationship between PANSS scores and BDNF levels of the patients yielded no correlations. Serum BDNF levels seem to be one of the indicators of schizophrenia and its progress; nevertheless, we still do not have sufficient information about this neurotropic factor. In light of our study, the neurodevelopmental changes that occur at disease onset of the illness prominently affect the progress of the illness, which highlights the importance of the treatment in the early stages.
- 1 May 2017
- Published by Elsevier in Psychiatry Research
- Vol. 251, 212-216
Thiol/disulfide homeostasis in untreated schizophrenia patients
- 1 May 2017
- Published by Elsevier in Psychiatry Research
- Vol. 251, 212-216
Thiol/disulfide homeostasis in untreated schizophrenia patients
- Open Access
- 31 March 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (sup1) , 47-84
9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology
(2017). 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology. Psychiatry and Clinical Psychopharmacology: Vol. 27, 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology Abstracts, pp. 47-84.
- 31 March 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (sup1) , 47-84
Open Access9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology
(2017). 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology. Psychiatry and Clinical Psychopharmacology: Vol. 27, 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology Abstracts, pp. 47-84.
- Open Access
- 31 March 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (sup1) , 1-46
9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology
(2017). 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology. Psychiatry and Clinical Psychopharmacology: Vol. 27, 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology Abstracts, pp. 1-46.
- 31 March 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (sup1) , 1-46
Open Access9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology
(2017). 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology. Psychiatry and Clinical Psychopharmacology: Vol. 27, 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology Abstracts, pp. 1-46.